News and Reports
-
HBM BioVentures realises a profit of EUR 41.9 million through the sale of PharmaSwiss to Valeant
1 February 2011Download -
MiCardia Corp.: Optimizing mitral valve repair
31 January 2011Download -
Nabriva reports positive results from phase II trial of Pleuromutilin antibiotic BC-3781 in ABSSSI
18 January 2011Download -
PTC Therapeutics completes enrollment of Phase 3 trial in Cystic Fibrosis
21 December 2010Download -
Vivacta closes £4 million financing
10 November 2010Download -
mtm laboratories extends series C financing round by EUR 7 million (USD 9.7 million)
8 November 2010Download -
MiCardia corporation receives CE mark clearance to market enCor dynamic mitral valve repair system in te European Union
3 November 2010Download -
Abbott and Enanta present positive initial results from phase 2 study in Hepatitis C
1 November 2010Download -
Pivotal data suggest PTC Therapeutics' Ataluren slows loss of walking ability in muscular distrophy patients
15 October 2010Download -
Interventional Spine Inc. announces issuance of key patents for the PERPOS PLS System
8 October 2010Download -
Interventional Spine, Inc. awarded the 2010 Best New Technology In Cervical Care Award
8 October 2010Download -
HBM BioVentures sells its investment in Sloning
7 October 2010Download -
Lux Biosciences reports phase 1 safety results and open label efficacy results for LX214, a potential best-in-class treament for Dry Eye
23 September 2010Download -
Successful sale of Asthmatx, a company from HBM BioVentures' portfolio, to Boston Scientific increases liquidity by CHF 4 million
21 September 2010Download -
Nabriva Therapeutic's Pleuromutilin Antibiotic BC-3781 shows therapeutic potential for skin and lung infections with both oral and IV dosing in non-clinical and clinical Phase I studies
10 September 2010Download -
Vivacta re-aligns management in preparation for £4 million finanacing round
26 August 2010Download -
Devax receives CE Mark for the AXXESS drug eluting bifurcation stent
29 July 2010Download -
HBM BioVentures largest public investment - Micrus - acquired by Johnson & Johnson
13 July 2010Download -
Lux Biosciences names Dean Mitchell President and CEO
1 July 2010Download -
HBM Partners to launch new M&A Report at BioBusiness Network conference (29-30 September 2010, Geneva)
30 June 2010Download -
Anthera enrolls first patients in pivotal Varespladib phase 3 clinical study
23 June 2010Download -
PTC Therapeutics awarded $5.4 million grant from the Wellcome Trust
7 June 2010Download -
Nabriva initiates phase II of pleuromutilin antibiotic BC-3781
2 June 2010Download -
Mpex Pharmaceuticals presents positive phase 2 clinical trial results of Aeroquin (MP-376) treatment in Cystic Fibrosis patients
17 May 2010Download -
FDA Advisory Committee to review Lux Biosciences' Uveitis candidate Luveniq
11 May 2010Download